This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
kit
KIT
KIT (CD117) is a type III RTK activated by SCF; KIT gain-of-function mutations in ~85% of GIST (exon 11 juxtamembrane most common) and KIT D816V in systemic mastocytosis; imatinib is first-line for GIST; avapritinib is approved for PDGFRA D842V and systemic mastocytosis.
Entry Metadata
| Field | Value |
|---|---|
| ID | kit |
| Name | KIT |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472-480. · PubMed 12181401
- Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265-1272. · PubMed 22453568